What other tests are important in his diagnostic workup?
Dr. David Fajgenbaum, Perelman School of Medicine, University of Pennsylvania, says that based on the positive ANA, SLE was suspected, and the patient was treated with high-dose corticosteroids with insufficient response, which prompted further testing. The absence of specific antibodies for SLE (negative dsDNA, anti-Smith and antiphospholipid antibodies) and normal complement levels ruled out SLE. Inactive urinary sediment and the absence of proteinuria with negative ANCA and antistreptolysin O titer made a systemic vasculitis or acute glomerulonephritis unlikely. Testing for EBV infection and blood cultures were negative. The patient was further tested for HIV by serology and HHV-6 by quantitative PCR, both of which were negative. A vascular endothelial growth factor (VEGF) level was found to be elevated at 500 pg/ mL. Coombs test was positive and haptoglobin was normal. The patient was tested for the presence of platelet autoantibodies, which were present.
The severity of the inflammatory syndrome can be determined by clinical presentation, disease course, and laboratory parameters. Typically, there is anemia, elevated sedimentation rate, elevated C-reactive protein, low albumin, and hypergammaglobulinemia. IL-6 is often elevated and in many cases drives the inflammatory syndrome. However, IL-6 is not specific for MCD and many inflammatory disorders and infections can give rise to an elevated IL-6. There is some variation from laboratory to laboratory in sensitivity of the assay. Lastly, IL-6 is not the crucial cytokine in all cases, and in some cases of iMCD; IL-6 is not elevated. The IL-6 in this patient was only elevated at 6 pg/mL (normal range: <5 pg/mL).
Guess the Diagnosis: Case 2
Mark F. is a 25-year-old law school student from Florida with a 3-week history of severe fatigue, night sweats, and weight loss; he has also reported high fevers for the past week. He did not complain of joint pain.
The patient was admitted for further assessment.
Mark’s SLE diagnosis was reviewed and further testing was performed:
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More